Oruka Therapeutics Inc
For the period ended Dec 31, 2024. Filed Mar 6, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 6, 2025
ORKA$104.56+1.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(In thousands, except share and per share data)
| December 31, | February 6, | |
|---|---|---|
| 2024 | 2024 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $61,575 | $— |
| Marketable securities, current | 314,073 | — |
| Subscription receivable | — | 1 |
| Prepaid expenses and other current assets | 1,221 | — |
| Total current assets | 376,869 | 1 |
| Marketable securities, long-term | 18,069 | — |
| Property and equipment, net | 162 | — |
| Operating lease right-of-use assets | 876 | — |
| Other non-current assets | 43 | — |
| Total assets | $396,019 | $1 |
| Liabilities, Convertible Preferred Stock and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $3,462 | $— |
| Accrued expenses and other current liabilities | 3,346 | — |
| Operating lease liability, current | 213 | — |
| Related party accounts payable and other current liabilities | 6,022 | — |
| Total current liabilities | 13,043 | — |
| Operating lease liability, non-current | 755 | — |
| Total liabilities | 13,798 | — |
| Commitments and contingencies (Note 13) | ||
| Series A convertible preferred stock, $0.0001 par value; no shares and 20,000,000 shares authorized as of December 31, 2024 and February 6, 2024, respectively; none issued and outstanding as of December 31, 2024 and February 6, 2024 | — | — |
| Series A non-voting convertible preferred stock, $0.001 par value; none authorized as of December 31, 2024 and February 6, 2024; none issued and outstanding as of December 31, 2024 and February 6, 2024 | — | — |
| Stockholders’ equity: | ||
| Series B non-voting convertible preferred stock, $0.001 par value; 251,504 and no shares authorized as of December 31, 2024 and February 6, 2024, respectively; 137,138 and no shares issued and outstanding as of December 31, 2024 and February 6, 2024, respectively | 2,931 | — |
| Common stock, $0.001 and $0.001 par value as of December 31, 2024 and February 6, 2024, respectively; 545,000,000 and 65,000,000 shares authorized, 37,440,510 and 3,197,975 shares issued and outstanding as of December 31, 2024 and February 6, 2024, respectively | 37 | — |
| Additional paid-in capital | 463,018 | 1 |
| Accumulated other comprehensive loss | (41) | — |
| Accumulated deficit | (83,724) | — |
| Total stockholders’ equity | 382,221 | 1 |
| Total liabilities, convertible preferred stock and stockholders’ equity | $396,019 | $1 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.